Table 1 Comparison of clinicopathologic features between TD-absent and TD-present gastric cancer patients before and after PSM

Overall

1714

201

491

191

Sex

 Male

1184

69.1

149

74.1

0.164

0.112

355

72.3

140

73.3

0.868

0.022

 Female

530

30.9

52

25.9

136

27.7

51

26.7

Age (years)

 < 58

917

53.5

78

38.8

< 0.001

0.298

205

41.8

77

40.3

0.798

0.029

 ≥ 58

797

46.5

123

61.2

286

58.2

114

59.7

 Mean (SD)

56.9 ± 11.1

61.0 ± 10.6

59.9 ± 10.6

60.7 ± 10.6

 Median (range)

58 (19–82)

62 (33–84)

61 (28–82)

62 (33–84)

Tumor location

 GEJ + Upper 1/3

431

25.1

68

33.8

0.013

0.217

163

33.2

65

34.0

0.964

0.023

 Middle 1/3

417

24.3

51

25.4

122

24.8

48

25.1

 Lower 1/3

866

50.5

82

40.8

206

42.0

78

40.8

Tumor size

 <3.2 cm

922

53.8

45

22.4

< 0.001

0.683

145

29.5

45

23.6

0.142

0.136

 ≥ 3.2 cm

792

46.2

156

77.6

346

70.5

146

76.4

 Mean (SD)

3.6 ± 2.1

5.1 ± 2.3

4.7 ± 2.3

4.9 ± 2.1

 Median (range)

3.0 (0.3–16.0)

4.5 (0.8–14.0)

4.5 (0.5–14)

6.0 (0.8–12)

Histologic grade

 Well-moderately

325

19.0

29

14.4

0.141

0.122

68

13.8

28

14.7

0.880

0.023

 Poorly

1389

81.0

172

85.6

423

86.2

163

85.3

T category

 T1

521

30.4

2

1.0

< 0.001

1.131

6

1.2

2

1.0

0.508

0.148

 T2

255

14.9

11

5.5

35

7.1

11

5.8

 T3

187

10.9

14

7.0

42

8.6

14

7.3

 T4a

731

42.6

158

78.6

393

80.0

153

80.1

 T4b

20

1.2

16

8.0

15

3.1

11

5.8

N category

 N0

790

46.1

16

8.0

< 0.001

1.023

50

10.2

16

8.4

0.846

0.100

 N1

308

18.0

36

17.9

97

19.8

36

18.8

 N2

280

16.3

50

24.9

132

26.9

49

25.7

 N3a

259

15.1

74

36.8

164

33.4

67

35.1

 N3b

77

4.5

25

12.4

TNM stage

 I

620

36.2

3

1.5

< 0.001

1.209

16

3.3

3

1.6

0.365

0.128

 II

398

23.2

22

10.9

66

13.4

22

11.5

 III

696

40.6

176

87.6

409

83.3

166

86.9

VELIPI

 Negative

996

58.1

54

26.9

< 0.001

0.666

147

29.9

54

28.3

0.738

0.037

 Positive

718

41.9

147

73.1

344

70.1

137

71.7

No. of retrieved LNs

 < 15

331

19.3

36

17.9

0.702

0.036

86

17.5

33

17.3

1.000

0.006

 ≥ 15

1383

80.7

165

82.1

405

82.5

158

82.7

 Mean (SD)

21.3 ± 8.4

21.9 ± 8.4

21.9 ± 8.3

22.0 ± 8.5

 Median (range)

20 (2–74)

20 (8–62)

20 (5–55)

20 (8–62)

Adjuvant treatment

 No

501

29.2

38

18.9

< 0.001

0.388

66

13.4

32

16.8

0.812

0.106

 Single drug

304

17.7

40

19.9

104

21.2

38

19.9

 Double drugs

625

36.5

63

31.3

177

36.0

63

33.0

 Triple drugs

167

9.7

43

21.4

101

20.6

41

21.5

 CRT

117

6.8

17

8.5

43

8.8

17

8.9